Biotechnology

Swedish biotech VERIGRAFT begins a pivotal trial for a personalized, lab-grown vein, offering hope for a true cure for millions with chronic venous insufficiency.

As funding expires for Wayne State's 35-year heart experiments on dogs, advocates and lawmakers urge the NIH to end a legacy of waste and suffering.

Venture capital leaders and national security experts caution that drug pricing controls and regulatory hurdles could cede America's biomedical edge to rivals.

A breakthrough in mycelium-based infection detection has prompted Mushrooms Inc. to halt a merger, betting its future on its own innovative biotech platform.

A new strategic partnership between Perceptive eClinical and Kayentis promises to ease clinical trial complexity by integrating key technology platforms.

Apimeds Pharmaceuticals accuses its Korean partner of an illegal board seizure, sparking a high-stakes legal fight in Delaware and Seoul over a broken merger.

Experic and Flurry Powders form a strategic alliance to accelerate complex therapies by combining advanced particle engineering with GMP manufacturing.

Xtressé's Xvie, an injectable therapy using extracellular vesicles, has been cleared for human trials, offering new hope for androgenetic alopecia.

With new financing from Avenue Capital, Turn Therapeutics bets big on its novel skin therapy, GX-03, to tackle multi-billion dollar dermatology markets.

Artis BioSolutions is opening a new synthetic DNA facility in Boston, aiming to reduce supply chain risks and accelerate next-gen medicine development.

A US-Japan biotech firm secures major funding to advance a first-in-class drug, offering new hope for millions with inherited blood disorders.

A new alliance between Discovery Life Sciences and Mindpeak aims to solve inconsistent biomarker interpretation, a critical bottleneck in cancer drug development.

Private equity firm Southfield Capital has acquired a majority stake in Metric Search, aiming to dominate the high-stakes recruitment market for niche talent.

The CRDMO giant posted a 16.7% revenue jump in 2025, driven by a massive pipeline expansion and a strategic pivot to next-generation biologics.

Merck's breakthrough PAH drug is now covered in several provinces, offering new hope. But what about its high cost and access for the rest of Canada?

A new platform is launching to connect pharma companies directly with 70+ global regulators, promising to slash approval times and speed patient access.

With positive safety data for its novel UC drug, a €530M cash reserve, and a new commercial chief, Abivax is poised for a major market entry.

A new Phase 2 trial is testing an inhaled version of a key IPF drug, aiming to reduce severe side effects and transform treatment for the fatal lung disease.

With a cash runway into 2027, the biotech firm prepares for critical data on its innovative bispecific antibody pipeline for hard-to-treat solid tumors.

Wilmington PharmaTech is doubling its API capacity, a key move to bolster the U.S. drug supply chain and reduce reliance on foreign manufacturing.